SI3345607T1 - Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE - Google Patents

Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE

Info

Publication number
SI3345607T1
SI3345607T1 SI200732194T SI200732194T SI3345607T1 SI 3345607 T1 SI3345607 T1 SI 3345607T1 SI 200732194 T SI200732194 T SI 200732194T SI 200732194 T SI200732194 T SI 200732194T SI 3345607 T1 SI3345607 T1 SI 3345607T1
Authority
SI
Slovenia
Prior art keywords
sost
agonist
administration
methods
bone growth
Prior art date
Application number
SI200732194T
Other languages
English (en)
Slovenian (sl)
Inventor
Debra L. Ellies
Original Assignee
Ossifi-Mab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39584303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3345607(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ossifi-Mab Llc filed Critical Ossifi-Mab Llc
Publication of SI3345607T1 publication Critical patent/SI3345607T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
SI200732194T 2006-12-29 2007-12-21 Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE SI3345607T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88264206P 2006-12-29 2006-12-29
EP18157578.8A EP3345607B1 (en) 2006-12-29 2007-12-21 Methods of altering bone growth by administration of sost or wise antagonist or agonist

Publications (1)

Publication Number Publication Date
SI3345607T1 true SI3345607T1 (sl) 2023-03-31

Family

ID=39584303

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200732194T SI3345607T1 (sl) 2006-12-29 2007-12-21 Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE

Country Status (12)

Country Link
US (9) US8178099B2 (enExample)
EP (3) EP2144613B1 (enExample)
JP (4) JP2010528002A (enExample)
DK (1) DK3345607T3 (enExample)
ES (2) ES2930183T3 (enExample)
FI (1) FI3345607T3 (enExample)
HU (1) HUE060822T2 (enExample)
LT (1) LT3345607T (enExample)
PL (1) PL3345607T3 (enExample)
PT (1) PT3345607T (enExample)
SI (1) SI3345607T1 (enExample)
WO (1) WO2009131553A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639020T3 (es) 1998-11-27 2017-10-25 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la substancia ósea
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US7585501B2 (en) * 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
JP2008511420A (ja) 2004-08-30 2008-04-17 スピネオベイションズ・インコポレーテッド 脊髄の椎間板内障害の治療の方法
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
SI3345607T1 (sl) * 2006-12-29 2023-03-31 Ossifi-Mab Llc Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
CN101925611A (zh) * 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
US8469961B2 (en) * 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
WO2010115932A1 (en) * 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
EP2558106A1 (en) 2010-04-16 2013-02-20 Novartis AG Methods and compositions for improving implant osseointegration
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
JP2014509588A (ja) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド 二特異性結合剤
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
ES2667554T3 (es) 2011-08-04 2018-05-11 Amgen Inc. Método para el tratamiento de los defectos de espacio óseo
KR20190120401A (ko) 2011-12-28 2019-10-23 암젠 인크 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
JP6770312B2 (ja) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9770415B2 (en) * 2012-11-27 2017-09-26 Southwest Research Institute Delivery substrates from aligned polymer biomaterials for tissue repair
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
CN107427604B (zh) 2015-01-16 2021-07-09 脊柱康健公司 治疗椎间盘的方法
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN106202901A (zh) * 2016-07-04 2016-12-07 奥美之路(北京)健康科技股份有限公司 骨龄远程在线判读系统
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CN111712573B (zh) 2018-02-12 2023-10-20 安沛治疗有限公司 针对骨硬化蛋白的适体及其用途
EP3774879B1 (en) 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants
WO2020163290A1 (en) * 2019-02-04 2020-08-13 Emory University Sclerostin inhibitors that promote bone morphogenetic protein expression
JP7572668B2 (ja) * 2019-07-12 2024-10-24 国立大学法人京都大学 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
CN111658821A (zh) * 2020-06-03 2020-09-15 深圳市百吉因生物科技有限公司 负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用
EP4687768A2 (en) 2023-04-06 2026-02-11 33 Medical, Inc. Minimally invasive compliant devices for total lumbar disc replacement
KR20260021016A (ko) 2023-06-02 2026-02-12 33 메디칼, 인크. 추간판성 통증의 치료를 위한 조성물, 및 그의 제조 및 사용 방법

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3050328C2 (de) 1980-04-07 1987-04-02 Berman, Joel, d/b/a Joel Berman Associates, New York, N.Y. Fensterrollo
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0381296B1 (en) 1984-04-30 1994-11-30 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5324819A (en) 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5344654A (en) 1988-04-08 1994-09-06 Stryker Corporation Prosthetic devices having enhanced osteogenic properties
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5298852A (en) * 1988-12-22 1994-03-29 Robert Bosch Gmbh Arrangement for and method of controlling a three-phase-generator in a vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5561173A (en) * 1990-06-19 1996-10-01 Carolyn M. Dry Self-repairing, reinforced matrix materials
AU658396B2 (en) * 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
US5656593A (en) * 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
US5863537A (en) 1992-02-19 1999-01-26 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
JP3347144B2 (ja) * 1993-01-12 2002-11-20 ジェネンテク，インコーポレイテッド 骨成長を誘発させるためのＴＧＦ−β製剤
TW303299B (enExample) * 1993-07-22 1997-04-21 Lilly Co Eli
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
DE19647853A1 (de) * 1996-11-19 1998-05-20 Bioph Biotech Entw Pharm Gmbh Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender Aktivität
US5939039A (en) * 1997-01-16 1999-08-17 Orthovita, Inc. Methods for production of calcium phosphate
AU6267798A (en) 1997-02-07 1998-08-26 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
US20020098222A1 (en) * 1997-03-13 2002-07-25 John F. Wironen Bone paste
US7041641B2 (en) * 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
EP0984795B1 (en) * 1997-04-22 2003-09-24 Washington Research Foundation Bone grafts and prostheses coated with tartrate-resistant acid phosphatase
US6025538A (en) 1998-11-20 2000-02-15 Musculoskeletal Transplant Foundation Compound bone structure fabricated from allograft tissue
ES2639020T3 (es) * 1998-11-27 2017-10-25 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la substancia ósea
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
WO2002067978A1 (en) 2001-02-23 2002-09-06 Wyeth Chondrogenic potential of human bone marrow-derived cd105+ cells by bmp
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
BR0209563A (pt) 2001-05-11 2004-12-07 Genome Theraupeutics Corp ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
TR201809678T4 (tr) * 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
WO2003070288A2 (en) 2001-10-12 2003-08-28 Inframat Corporation Coated implants and methods of coating implants
CA2465499A1 (en) 2001-11-08 2003-05-15 Merck & Co., Inc. Compositions and methods for treating osteoporosis
AU2003207512B2 (en) * 2002-01-10 2008-06-12 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
JP2005519067A (ja) * 2002-01-17 2005-06-30 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム トロンビンペプチド誘導体を用いた骨成長および軟骨形成の刺激
JP3646167B2 (ja) 2002-02-19 2005-05-11 独立行政法人産業技術総合研究所 フォスフォフォリンを含む複合生体材料
WO2003073991A2 (en) * 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
US7166133B2 (en) * 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20040002770A1 (en) 2002-06-28 2004-01-01 King Richard S. Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof
EP1539239A4 (en) * 2002-07-02 2005-09-14 Smithkline Beecham Corp NEW STABLE FORMULATION
US20040023322A1 (en) * 2002-08-01 2004-02-05 Goodheart Clyde R. Method of producing non-recombinant BMP-2 and use thereof
KR20040023356A (ko) 2002-09-11 2004-03-18 현대모비스 주식회사 파킹브레이크 작동시 출발제한 시스템 및 그 방법
AU2002335562B2 (en) 2002-09-30 2007-07-05 Regen Biotech, Inc. Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers
JP3851602B2 (ja) * 2002-10-02 2006-11-29 ペンタックス株式会社 骨形成治療デバイス
CA2526845A1 (en) 2003-06-06 2005-03-31 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
US7943393B2 (en) 2003-07-14 2011-05-17 Phynexus, Inc. Method and device for extracting an analyte
US6976816B2 (en) 2003-08-01 2005-12-20 Dana Corporation Combination lock washer and spindle bearing assembly
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
WO2005070439A1 (en) * 2004-01-09 2005-08-04 Regeneration Technologies Inc. Implant comprising a human muscle tissue matrix
US7189263B2 (en) 2004-02-03 2007-03-13 Vita Special Purpose Corporation Biocompatible bone graft material
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) * 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
CA2567805A1 (en) * 2004-05-27 2005-12-15 Acceleron Pharma Inc. Tgf derepressors and uses related thereto
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
JP2008517660A (ja) * 2004-10-22 2008-05-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 生物剤を送達する中空かつ多孔質の整形外科用または歯科用のインプラント
WO2006072622A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
US7531533B2 (en) * 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
US8071574B2 (en) 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20060198863A1 (en) 2005-03-03 2006-09-07 Musculoskeletal Transplant Foundation Ceramic composition for filling bone defects
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP2006320442A (ja) 2005-05-18 2006-11-30 Toshiba Ceramics Co Ltd リン酸カルシウム系骨補填材
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
WO2006135734A2 (en) 2005-06-10 2006-12-21 The Regents Of The University Of California Compositions and methods for altering bone density and bone patterning
BRPI0611800A2 (pt) * 2005-06-15 2008-12-09 Schering Corp formulaÇço estÁvel de anticorpo
ES2402651T3 (es) 2005-09-09 2013-05-07 Agnovos Healthcare, Llc Cemento sustituto de injerto óseo de material compuesto y artículos producidos del mismo
EP2431060B1 (en) 2005-11-17 2020-04-08 BioMimetic Therapeutics, LLC Maxillofacial bone augmentation using RHPDGF-BB and a biocompatible matrix
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
WO2008133722A2 (en) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
SI3345607T1 (sl) * 2006-12-29 2023-03-31 Ossifi-Mab Llc Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
EP2131860B1 (en) 2007-03-20 2013-12-18 Eli Lilly & Company Anti-sclerostin antibodies
EP2139507A4 (en) 2007-04-27 2012-06-06 Unigene Lab Inc METHODS AND COMPOSITIONS FOR PROMOTING AND CONSERVING BONE GROWTH
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP6511233B2 (ja) 2014-08-28 2019-05-15 株式会社竹中工務店 柱脚部と鉄骨梁との接合構造

Also Published As

Publication number Publication date
US20260062470A1 (en) 2026-03-05
US20080160060A1 (en) 2008-07-03
US20130195856A1 (en) 2013-08-01
EP2144613B1 (en) 2018-03-21
EP3345607B1 (en) 2022-10-26
US8178099B2 (en) 2012-05-15
ES2666650T3 (es) 2018-05-07
WO2009131553A2 (en) 2009-10-29
EP2144613A2 (en) 2010-01-20
ES2930183T3 (es) 2022-12-07
JP2010528002A (ja) 2010-08-19
US20120201815A1 (en) 2012-08-09
PT3345607T (pt) 2022-11-21
US11807681B2 (en) 2023-11-07
US20240360207A1 (en) 2024-10-31
PL3345607T3 (pl) 2023-01-09
US20150086571A1 (en) 2015-03-26
EP3345607A1 (en) 2018-07-11
US11891438B2 (en) 2024-02-06
US8877196B2 (en) 2014-11-04
FI3345607T3 (fi) 2022-11-30
EP4176884A1 (en) 2023-05-10
US20230226086A1 (en) 2023-07-20
US11608373B2 (en) 2023-03-21
US20170044248A1 (en) 2017-02-16
JP2017014263A (ja) 2017-01-19
DK3345607T3 (da) 2022-11-21
US20230357377A1 (en) 2023-11-09
JP2018199725A (ja) 2018-12-20
WO2009131553A3 (en) 2010-04-29
HUE060822T2 (hu) 2023-04-28
LT3345607T (lt) 2023-01-10
JP2014074046A (ja) 2014-04-24

Similar Documents

Publication Publication Date Title
PT3345607T (pt) Métodos para alterar o crescimento ósseo por administração de antagonista ou agonista de sost ou wise
HUS000509I2 (hu) Abemaciklib vagy egy gyógyászatilag elfogadható sója
IL196181A0 (en) Substituted n-phenylmethyl-5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
ZA200904446B (en) Methods of use for cyclopamine analogs
ZA201106538B (en) Compositions and methods for increasing muscle growth
EP2117448A4 (en) EDDY ANCHOR BOLT
IL194862A0 (en) Maleate co-crystal of azd1152
IL196706A0 (en) Crystalline forms of rapamycin analogs
AP2008004406A0 (en) Methods of managing timberland
ZA200808245B (en) Compositions and methods for inducing bone growth and inhibiting bone loss
GB0705854D0 (en) Methods of construction
IL193456A0 (en) Incapacity monitor
IL206479A0 (en) Crystalline forms of palonosetron hydrochloride
AP2784A (en) Methods of managing timberland
ZA200806508B (en) Salt of CD80 Antagonist
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
IL197192A0 (en) Preparation of decahalodiphenyl ethane
ZA200810726B (en) Substituted N-Phenylmethyl -5-OXO-Proline-2-Amides AS P2X7-Receptor Antagonists and their methods of use
IL216365A0 (en) Methods of administration of thrombopoietin agonist compounds
IL200826A0 (en) Method for evaluation of tissue preservation solution
ZA200900740B (en) Crystalline forms of rapamycin analogs
EG24395A (en) New method for depittering of apricot seed
ZA200900669B (en) Spinal prosthesis with offset anchors
GB0601140D0 (en) Tissue monitor
AU2007902502A0 (en) Game fishing chair